Saturday 31 October 2026
Export LLY’s income statement to Excel — free account
Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
1,415.16
41.46
+3.02%
Follow LLY
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
8 | 7 | 8 | 9 |
| 96.47% | 101.16% | 107.46% | 102.29% | ||
| 19.33% | 21.59% | 24.54% | 21.97% | ||
ROIC |
25.82% | 26.61% | 30.18% | 26.33% | |
Return on Tangible Assets |
41.61% | 45.79% | 56.50% | 57.79% | |
Average Days of Receivables |
119.52 | 112.87 | 106.99 | 107.56 | |
Free Cash Flow per Share |
10.34 | 10.00 | 13.22 | 20.38 | |
Free Cash Flow |
9,271.80 | 8,972.00 | 11,823.00 | 18,190.00 | |
Capital Expenditures |
(6,790.50) | (7,841.00) | (8,657.00) | (9,893.00) | |
| Other line items | |||||
Cash ROIC |
12.42% | 11.76% | 15.59% | 18.61% | |
Accounts Receivable Turnover |
3.77 | 3.90 | 4.11 | 3.92 | |
Accounts Payable Turnover |
2.82 | 2.57 | 2.93 | 2.60 | |
Inventory Turnover |
1.03 | 1.04 | 1.04 | 0.95 | |
Average Days of Payables |
154.26 | 177.65 | 147.98 | 168.70 | |
Days of Inventory on Hand |
440.85 | 453.91 | 427.53 | 463.51 | |
Tax Rate |
(0.18) | (0.20) | (0.19) | (0.20) | |
Research and Development Expense of Revenue |
21.13% | 20.46% | 19.53% | 18.32% | |
Selling, General and Administrative Expense of Revenue |
17.48% | 17.02% | 16.00% | 15.36% | |
Share Based Compensation of Revenue |
1.06% | 0.96% | 0.88% | 0.81% | |
Interest Coverage |
— | — | — | 83.46 | |
Operating CF/Net income |
0.87 | 0.81 | 0.81 | 1.05 | |
Depreciation/Fixed assets |
0.09 | 0.08 | 0.08 | 0.07 | |
Capex/Depreciation |
(3.58) | (3.93) | (4.24) | (4.71) | |
Revenue per Share |
66.25 | 72.64 | 80.77 | 89.27 | |
Operating CF per Share |
17.91 | 18.74 | 22.90 | 31.47 | |
Capex per Share |
(7.57) | (8.74) | (9.68) | (11.09) | |
Capex to Sales |
0.11 | 0.12 | 0.12 | 0.12 |
Columns are period end dates